Asian Market Companies That May Be Priced Below Their Estimated Value
As Asian markets navigate a complex landscape of global economic shifts and technological advancements, investors are increasingly on the lookout for opportunities that may be overlooked by others. In this environment, identifying stocks that appear undervalued can be a strategic move, as these companies might offer potential growth when market conditions stabilize or improve.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Shizuki Electric (TSE:6994) | ¥1220.00 | ¥2309.36 | 47.2% |
| Rakus (TSE:3923) | ¥1047.50 | ¥2062.91 | 49.2% |
| PAL GROUP Holdings (TSE:2726) | ¥1468.00 | ¥2880.42 | 49% |
| Kumagai GumiLtd (TSE:1861) | ¥1309.00 | ¥2429.20 | 46.1% |
| Kingnet Network (SZSE:002517) | CN¥16.17 | CN¥31.44 | 48.6% |
| Ichikoh Industries (TSE:7244) | ¥569.00 | ¥1074.16 | 47% |
| Double Medical Technology (SZSE:002901) | CN¥41.34 | CN¥79.52 | 48% |
| China Coal Energy (SEHK:1898) | HK$10.43 | HK$20.08 | 48.1% |
| Cheil Worldwide (KOSE:A030000) | ₩17680.00 | ₩34133.77 | 48.2% |
| BuySell TechnologiesLtd (TSE:7685) | ¥2805.00 | ¥5572.99 | 49.7% |
We'll examine a selection from our screener results.
Gushengtang Holdings (SEHK:2273)
Overview: Gushengtang Holdings Limited is an investment holding company that offers healthcare services in the People’s Republic of China and Singapore, with a market cap of HK$5.77 billion.
Operations: The company generates revenue through the sale of healthcare products amounting to CN¥27.45 million and the provision of healthcare solutions totaling CN¥3.38 billion.
Estimated Discount To Fair Value: 35%
Gushengtang Holdings appears undervalued, trading 35% below its estimated fair value and more than 20% below future cash flow value. Recent earnings showed a net income increase to CNY 220.71 million from CNY 151.65 million year-on-year, with sales rising to CNY 1.65 billion. The company declared a HK$1.15 interim dividend per share for the first half of 2026, indicating solid cash flow support despite moderate forecasted annual earnings growth of around 11%.
- Our comprehensive growth report raises the possibility that Gushengtang Holdings is poised for substantial financial growth.
- Click here and access our complete balance sheet health report to understand the dynamics of Gushengtang Holdings.
Mega Lifesciences (SET:MEGA)
Overview: Mega Lifesciences Public Company Limited, with a market cap of THB30.30 billion, operates in the health sector by manufacturing and selling health food supplements, prescription pharmaceuticals, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods.
Operations: The company's revenue is primarily derived from its Brands segment, generating THB9.22 billion, followed by Distribution at THB4.91 billion and Original Equipment Manufacture (OEM) contributing THB377.82 million.
Estimated Discount To Fair Value: 29.5%
Mega Lifesciences is trading at THB34.75, significantly below its estimated future cash flow value of THB49.28, suggesting it may be undervalued. Recent earnings for Q2 2026 show a net income rise to THB514.61 million from THB390.92 million year-on-year, with revenue increasing to THB3.62 billion from THB3.44 billion. Despite slower-than-market forecasted revenue growth of 5.3% annually, analysts agree on a potential stock price increase of 22.9%.
- In light of our recent growth report, it seems possible that Mega Lifesciences' financial performance will exceed current levels.
- Click to explore a detailed breakdown of our findings in Mega Lifesciences' balance sheet health report.
CURVES HOLDINGS (TSE:7085)
Overview: CURVES HOLDINGS Co., Ltd. operates and manages women's fitness clubs under the Curves brand in Japan and internationally, with a market cap of ¥82.70 billion.
Operations: The company generates revenue primarily from its Curves Business segment, amounting to ¥41.39 billion.
Estimated Discount To Fair Value: 37.8%
CURVES HOLDINGS is trading at ¥898, notably below its future cash flow estimate of ¥1,444.33, indicating undervaluation. The company recently completed a share buyback of 3 million shares for ¥2.76 billion to enhance capital efficiency and shareholder returns. Despite slower earnings growth forecasts compared to the Japanese market, revenue is expected to grow faster than the market average at 9% annually. Recent earnings showed sales increased from ¥27.74 billion to ¥31.57 billion year-on-year.
- According our earnings growth report, there's an indication that CURVES HOLDINGS might be ready to expand.
- Unlock comprehensive insights into our analysis of CURVES HOLDINGS stock in this financial health report.
Seize The Opportunity
- Click through to start exploring the rest of the 80 Undervalued Asian Stocks Based On Cash Flows now.
- Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com